[1]黄维,李英,龙强,等.中晚期宫颈癌患者调强放疗与同步推量调强放疗预后比较[J].国际放射医学核医学杂志,2016,40(6):429-434.[doi:10.3760/cma.j.issn.1673-4114.2016.06.006]
　Huang Wei,Li Ying,Long Qiang,et al.Clinical effects of IMRT and simultaneous integrated boost-intensity modulated radiation therapy:a comparative study of 277 patients with advanced cervical cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):429-434.[doi:10.3760/cma.j.issn.1673-4114.2016.06.006]
点击复制

中晚期宫颈癌患者调强放疗与同步推量调强放疗预后比较(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第6期
页码:
429-434
栏目:
论著
出版日期:
2016-11-25

文章信息/Info

Title:
Clinical effects of IMRT and simultaneous integrated boost-intensity modulated radiation therapy:a comparative study of 277 patients with advanced cervical cancer
作者:
黄维;  李英;  龙强;  鲁文力;  姜庆丰;  谭本旭;  田丽娟;  罗弋;  肖英;  方文姬
400016, 重庆医科大学附属第一医院肿瘤科
Author(s):
Huang Wei;  Li Ying;  Long Qiang;  Lu Wenli;  Jiang Qingfeng;  Tan Benxu;  Tian Lijuan;  Luo Yi;  Xiao Ying;  Fang Wenji
Department of Oncology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
关键词:
宫颈肿瘤; 预后; 调强放射治疗; 同步推量调强放疗
Keywords:
Uterine cervical neoplasms; Prognosis; Intensity-modulated radiation therapy; Simultaneous integrated boost-intensity modulated radiation therapy Fund program:Medical Research Fundation of Chongqing Heath Bureau(2013-1-009)
DOI:
10.3760/cma.j.issn.1673-4114.2016.06.006
摘要:
目的 探讨同步推量调强放疗（SIB-IMRT）技术治疗中晚期宫颈癌患者的不良反应、远期疗效及相关预后因素。方法 回顾性分析2009年1月至2015年6月收治的277例中晚期未手术的宫颈癌患者，其中70例行IMRT，207例行SIB-IMRT。比较中晚期宫颈癌患者行IMRT与SIB-IMRT后的不良反应，并进行远期疗效及预后因素分析。采用Kaplan-Meier法计算生存率，Cox法行多因素预后分析。结果 IMRT组与SIB-IMRT组的随访率均为100%。与IMRT相比，SIB-IMRT未增加患者直肠及膀胱的急性毒性反应（χ2=0.306和0.971，P均>0.05）和远期毒性反应（χ2=0.014和0.381，P均>0.05）。IMRT组及SIB-IMRT组患者1年总生存率（OS）分别为100%和99.5%，3年OS分别为75.0%和84.7%，差异无统计学意义（χ2=0.339和0.674，P均>0.05）。患者年龄和治疗前淋巴结状态是所有入组患者（χ2=7.971和15.938，P均<0.05）及SIB-IMRT组患者（χ2=7.503和10.048，P均<0.05）生存的预后影响因素。结论 初步结果表明SIB-IMRT技术安全可行，且可以减少后装治疗次数，减轻患者后装治疗的不适及痛苦。对于中晚期宫颈癌患者，SIB-IMRT是一种可尝试的外照射技术。
Abstract:
Objective To explore the toxicity, long-term overall survival(OS), and prognostic factors in advanced cervical cancer treated with IMRT and simultaneous integrated boost-intensity modulated radiation therapy(SIB-IMRT). Methods A retrospective analysis was performed on 277 patients with advanced cervical cancer. These patients were admitted from January 2009 to June 2015. Among the 277 patients, 70 patients received IMRT, and 207 patients received SIB-IMRT. Toxicities, survival rates, and prognostic factors were compared between the two groups. The Kaplan-Meier method was used to calculate the survival rates, and the Cox model was used for multivariate prognostic analysis. Results The follow-up rate was 100% in both the IMRT and SIB-IMRT groups. Compared with IMRT, SIB-IMRT showed no significant differences in acute proctitis and cystitis toxicities(χ2=0.306, 0.971, both P>0.05), as well as in long-term toxicity(χ2=0.014, 0.381, both P>0.05). The 1-year OS rates for the IMRT and SIB-IMRT groups were 100% and 99.5%, respectively, and the 3-year OS rates were 75.0% and 84.7%, correspondingly(χ2=0.339, 0.674, both P>0.05). The age and status of the pretreatment lymph nodes were the prognostic factors for all patients(χ2=7.971, 15.938, both P<0.05), including the SIB-IMRT group(χ2=7.503, 10.048, both P<0.05) in terms of OS. Conclusion Results indicated that SIB-IMRT can feasibly treat advanced cervical cancer. SIB-IMRT is a promising alternative treatment for patients who are not fit for brachytherapy treatment; this method also helps to reduce treatment fractions. Hence, SIB-IMRT is a recommended external beam technology for cervical cancer treatment.

参考文献/References:

[1] 张瑾, 吴玉梅, 孔为民, 等.763例Ⅲ期宫颈癌不同放疗方法的疗效分析[J].中华放射肿瘤学杂志, 2008, 17(5):364-367. DOI:10.3321/j.issn:1004-4221.2008.05.009.Zhang J, Wu YM, Kong WM, et al.Treatment results of different radiotherapy for 763 patients with advanced cervical cancer[J].Chin J Radiat Oncol, 2008, 17(5):364-367.
[2] 黄建敏, 潘莉萍, 李冬雪.PET和PET-CT在宫颈癌中的应用价值[J].国际放射医学核医学杂志, 2007, 31(2):112-114. DOI:10.3760/cma.j.issn.1673-4114.2007.02.016.Huang JM, Pan LP, Li DX.The application of PET and PET-CT in cervical cancer[J].Int J Radiat Med Nucl Med, 2007, 31(2):112-114.
[3] Du XL, Tao J, Sheng XG, et al.Intensity-modulated radiation therapy for advanced cervical cancer:a comparison of dosimetric and clinical outcomes with conventional radiotherapy[J].Gynecol Oncol, 2012, 125(1):151-157. DOI:10.1016/j.ygyno.2011.12.432.
[4] Chen CC, Lin JC, Jan JS, et al.Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer[J].Gynecol Oncol, 2011, 122(1):9-13. DOI:10.1016/j.ygyno.2011.03.034.
[5] Zhang G, Fu C, Zhang Y, et al.Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases:a retrospective review in a single institution[J].Int J Gynecol Cancer, 2012, 22(7):1220-1225. DOI:10.1097/IGC.0b013e3182643b7c.
[6] Marnitz S, K?hler C, Burova E, et al.Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer:analysis of feasibility and early toxicity[J/OL].Int J Radiat Oncol Biol Phys, 2012, 82(2):e137-e143[2016-09-13].http://www.sciencedirect.com/science/acticle/pii/S0360301610036382. DOI:10.1016/j.ijrobp.2010.10.066.
[7] Vandecasteele K, De Neve W, De Gersem W, et al.Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer.Treatment planning, quality control, and clinical implementation[J].Strahlenther Onkol, 2009, 185(12):799-807. DOI:10.1007/s00066-009-1986-8.
[8] Koh WY, Lim K, Tey J, et al.Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer[J].Gynecol Oncol, 2013, 131(1):93-98. DOI:10.1016/j.ygyno.2013.07.102.
[9] Boyle J, Craciunescu O, Steffey B, et al.Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies[J].Gynecol Oncol, 2014, 135(2):239-243. DOI:10.1016/j.ygyno.2014.08.037.
[10] Marnitz S, Stromberger C, Kawagan-Kagan M, et al.Helical tomotherapy in cervical cancer patients:simultaneous integrated boost concept:technique and acute toxicity[J].Strahlenther Onkol, 2010, 186(10):572-579. DOI:10.1007/s00066-010-2121-6.
[11] Guerrero M, Li XA, Ma L, et al.Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer:radiobiological and dosimetric considerations[J].Int J Radiat Oncol Biol Phys, 2005, 62(3):933-939. DOI:10.1016/j.ijrobp.2004.11.040.
[12] Harris EE, Latifi K, Rusthoven C, et al.Assessment of organ motion in postoperative endometrial and cervical cancer patients treated with intensity-modulated radiation therapy[J].Int J Radiat Oncol Biol Phys, 2011, 81(4):E645-E650. DOI:10.1016/j.ijrobp.2011.01.054.
[13] Macchia G, Cilla S, Deodato F, et al.Intensity-modulated extended-field chemoradiation plus simultaneous integrated boost in the pre-operative treatment of locally advanced cervical cancer:a dose-escalation study[J/OL].Br J Radiol, 2015, 88(1055):20150385[2016-09-13].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743458. DOI:10.1259/bjr.20150385.
[14] 朱卫国, 于长华, 李涛, 等.国产奈达铂用于宫颈癌同步放化疗的剂量递增试验[J].中华肿瘤杂志, 2011, 33(7):525-526. DOI:10.3760/cma.j.issn.0253-3766.2011.07.011.Zhu WG, Yu CH, Li T, et al.Dose escalation of domestic nedaplatin used in concurrent chemoradiotherapy for cervical cancer[J].Chin J Oncol, 2011, 33(7):525-526.
[15] Gandhi AK, Sharma DN, Rath GK, et al.Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma:a prospective randomized study[J].Int J Radiat Oncol Biol Phys, 2013, 87(3):542-548. DOI:10.1016/j.ijrobp.2013.06.2059.

相似文献/References:

[1]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
　Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]刘道佳,唐明灯,林端瑜,等.18F-FDG SPECT-CT在宫颈癌监测中的价值[J].国际放射医学核医学杂志,2010,34(3):155.
　LIU Dao-jia,TANG Ming-deng,LIN Duan-yu,et al.The value of 18F-FDG SPECT-CT in detecting recurrence or metastasis of cervical cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):155.
[4]张文学,姜炜,只达石.全中枢系统合并局部加量照射治疗颅内生殖细胞瘤[J].国际放射医学核医学杂志,2008,32(2):122.
　ZHANG Wen-xue,JIANG Wei,ZHI Da-shi.The prognostics analysis of whole nervous system irradiation combined local dose accumulating for patients with intracranial germinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):122.
[5]张文学,姜炜,只达石.全中枢系统合并局部后颅窝加量照射髓母细胞瘤疗效分析[J].国际放射医学核医学杂志,2007,31(6):384.
　ZHANG Wen-xue,JIANG Wei,ZHI Da-shi.The Prognostic Analysis of Whole Nervous System and Posterior Fossa Irradiation for Patients with Cerebellar Medulloblastoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):384.
[6]黄建敏,潘莉萍,李冬雪.PET和PET-CT在宫颈癌中的应用价值[J].国际放射医学核医学杂志,2007,31(2):112.
　HUANG Jian-min,PAN Li-ping,LI Dong-xue.The application of PET and PET-CT in cervical cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):112.
[7]张文学,姜炜,吕仲虹,等.常规放疗结合后程立体定向放射治疗老年非小细胞肺癌患者的预后分析[J].国际放射医学核医学杂志,2007,31(2):125.
　ZHANG Wen-xue,JIANG Wei,LV Zhong-hong,et al.Prognostics analysis of common radiotherapy combined stereotactic radiotherapy for non-small cell lung cancer of old patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):125.
[8]宋少莉,黄钢.18F-氟脱氧葡萄糖PET监测实体瘤放化疗疗效的应用进展[J].国际放射医学核医学杂志,2007,31(5):284.
　SONG Shao-Li,HUANG Gang.The development of monitoring chemotherapy and radiotherapy of solid tumor by 18F-fluorodeoxyglucose PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):284.
[9]李红艳,贺桂芳,陈志华.宫颈癌辐射敏感性相关基因的研究进展[J].国际放射医学核医学杂志,2007,31(1):44.
　LI Hong-yan,HE Gui-fang,CHEN Zhi-hua.The development of genes associated with radiosensitivity of cervical cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):44.
[10]姜炜,郭阳,徐玲,等.立体定向放射治疗胰腺癌[J].国际放射医学核医学杂志,2007,31(1):55.
　JIANG Wei,GUO Yang,XU Ling,et al.Stereotactic radiotherapy for pancreatic cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):55.

备注/Memo

备注/Memo:
收稿日期:2016-09-13。
基金项目:重庆市卫生局医学科研计划重点项目（2013-1-009）
通讯作者:李英,Email:peiyuanx@163.com
更新日期/Last Update: 1900-01-01